Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

93.70USD
8:33pm IST
Change (% chg)

$0.35 (+0.37%)
Prev Close
$93.35
Open
$93.66
Day's High
$94.09
Day's Low
$93.38
Volume
518,064
Avg. Vol
2,708,061
52-wk High
$109.49
52-wk Low
$81.79

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $258,496.09
Shares Outstanding(Mil.): 2,769.11
Dividend: 0.75
Yield (%): 3.21

Financials

  JNJ.N Industry Sector
P/E (TTM): 16.44 35.45 35.59
EPS (TTM): 5.68 -- --
ROI: 14.75 15.51 14.96
ROE: 21.59 16.08 15.84
Search Stocks

J&J sells popular Splenda sugar substitute to Heartland Food

- Johnson & Johnson on Tuesday said it was selling its widely used Splenda sugar substitute to privately held Heartland Food Products Group in order to focus on other consumer brands.

26 Aug 2015

UPDATE 2-J&J sells popular Splenda sugar substitute to Heartland Food

Aug 25 - Johnson & Johnson on Tuesday said it was selling its widely used Splenda sugar substitute to privately held Heartland Food Products Group in order to focus on other consumer brands.

26 Aug 2015

Interpublic reports better-than-expected revenue

- Advertising company Interpublic Group of Cos Inc's revenue trumped expectations for the seventh straight quarter as higher advertising spending by U.S. businesses made up for the strong dollar's impact on international revenue.

22 Jul 2015

UPDATE 2-J&J 2nd-qtr sales wilt on strong dollar, weak device sales

July 14 - Johnson & Johnson on Tuesday reported sharply lower sales in the second quarter, and cited a stronger U.S. dollar, disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition.

14 Jul 2015

BRIEF-J&J CFO sees little impact from Greece debt resolution

* J&J CFO says does not expect Greece debt resolution to affect company sales, earnings unless there is significant change from expected resolution

14 Jul 2015

J&J profit rises 4 pct on pharma sales

July 14 - Johnson & Johnson reported a 4 percent rise in quarterly profit as sales of its mainstay older drugs managed to offset the impact of a strong dollar on overseas revenue.

14 Jul 2015

U.S. current account widens on weak exports, overseas profits

WASHINGTON - The U.S. current account deficit widened in the first quarter to its highest level since 2012 likely due to the strong dollar's drag on overseas profits and exports.

18 Jun 2015

U.S. industrial output hurt by weakness in manufacturing, mining

WASHINGTON - U.S. industrial production unexpectedly fell in May as manufacturing and mining activity remained weak, a sign that a strong dollar and spending cuts in the energy sector continued to constrain economic growth.

15 Jun 2015

WRAPUP 2-U.S. industrial output hurt by weakness in manufacturing, mining

WASHINGTON, June 15 - U.S. industrial production unexpectedly fell in May as manufacturing and mining activity remained weak, a sign that a strong dollar and spending cuts in the energy sector continued to constrain economic growth.

15 Jun 2015

Genmab shares rise on cancer drug's FDA licence application

COPENHAGEN, June 8 - Shares in Genmab rose almost 3 percent on Monday after partner Johnson and Johnson's announcement late on Friday that the companies have applied to U.S. authorities for a licence to market their blood cancer drug daratumumab.

08 Jun 2015

Earnings vs. Estimates

Search Stocks